Cymabay Therapeutics
- Pharmaceutical Preparations
- Newark, California
Compensation history
Top executives at Cymabay Therapeutics received an average of $1M per person in annual compensation from 2012 to 2022.
Average pay of disclosed executives at Cymabay Therapeutics
By year
Executives
We found ten executives who work or worked at Cymabay Therapeutics.
Sujal Shah
Cymabay Therapeutics
Chief Executive Officer
Charles McWherter
Cymabay Therapeutics
President of R&D
Paul Quinlan
Cymabay Therapeutics
General Counsel
Dennis Kim
Cymabay Therapeutics
Chief Medical Officer
Lewis Stuart
Cymabay Therapeutics
Chief Commercial Officer
Janet Dorling
Cymabay Therapeutics
Former Chief Commercial Officer
Pol Boudes
Cymabay Therapeutics
Chief Medical Officer
Klara Dickinson
Cymabay Therapeutics
Chief Regulatory and Compliance Officer
News
Cymabay Therapeutics CEO Sujal Shah's 2022 pay rises 16% to $2.6M
April 19, 2023
Cymabay Therapeutics CEO Sujal Shah's 2021 pay slips 16% to $2.2M
April 26, 2022
Cymabay Therapeutics CEO Sujal Shah's 2019 pay jumps 32% to $2.6M
May 15, 2020
Cymabay Therapeutics General Counsel Paul Quinlan receives $3M in 2018
April 26, 2019
About Cymabay Therapeutics
- Industry classifications
- DivisionManufacturing
- Major groupChemicals And Allied Products
- Industry groupDrugs
- IndustryPharmaceutical Preparations
- Address7575 Gateway Boulevard, Suite 110, Newark, California 94560
- Phone510-293-8800
- Fiscal year endDecember 31
- Former names
- METABOLEX, INC.Until November 9, 2009
- METABOLEX INCUntil March 4, 2009
Source: SEC filings on April 19, 2023, April 26, 2022, May 15, 2020, April 26, 2019, April 20, 2018, April 19, 2017, April 21, 2016, and April 21, 2014.